ALEXANDRIA, Va., April 7 -- United States Patent no. 12,595,306, issued on April 7, was assigned to Novartis AG (Basel, Switzerland).
"TREM2 stabilizing antibodies" was invented by Verena Brand (Munich), Dominik Feuerbach (Mullheim, Germany), Fabrizio Gasparini (Lausen, Switzerland), Nathalie George (Village-Neuf, France), Eveline Schaadt (Oberhaching, Germany), Derya Shimshek (Loerrach, Germany), Honnappa Srinivas (Brugg, Switzerland), Markus Waldhuber (Munich) and Rainer Wilcken (Basel, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using the...